Travere Therapeutics Inc. (TVTX)
NASDAQ
Closed
Oct 19, 2026
Day's Range
49.7452 wk Range
22.59Overview - TVTX - Travere Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
4.80B
P/E (Trailing)
‪-174.10‬
P/E (Forward)
‪8.96‬
PEG Ratio
‪-1.05‬
Price / Sales (TTM)
‪8.05‬
Price / Book
‪194.42‬
EV / EBITDA
‪209.62‬
Profitability
Gross Margin
‪94.55%‬
Profit Margin
‪-7.35%‬
Operating Margin
‪2.33%‬
Return on Assets
‪-3.73%‬
Return on Equity
‪-236.35%‬
Ownership
Shares Outstanding
94.17M
Float
93.21M
Short % of Shares Outstanding
‪17.48%‬
Held by Insiders
‪0.69%‬
Held by Institutions
‪116.01%‬
Price stats
Beta
‪1.14‬
50-Day Avg
‪61.37‬
200-Day Avg
‪45.82‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
15 analysts
Average price target
‪$ 74.14‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - TVTX - Travere Therapeutics Inc.
Peers - TVTX - Travere Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- TVTXNASDAQTravere Therapeutics Inc.4.75BMarket Cap+44.94%52-week change-174.10P/E (Trailing)‪-7.35%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.72BMarket Cap+5.31%52-week change148.09P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - TVTX - Travere Therapeutics Inc.
About
Travere Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with rare kidney, liver, and metabolic diseases. Its current commercial portfolio includes FILSPARI, a treatment for certain kidney disorders, along with legacy rare-disease products such as…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
